Breaking News

Tweet TWEET

Stock Price Movements and Positive Quarterly Results - Research Report on Waters, PerkinElmer, DENTSPLY, NxStage, and ICON

  Stock Price Movements and Positive Quarterly Results - Research Report on
               Waters, PerkinElmer, DENTSPLY, NxStage, and ICON

PR Newswire

NEW YORK, November 14, 2013

NEW YORK, November 14, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Waters
Corporation (NYSE: WAT),

PerkinElmer, Inc. (NYSE: PKI), DENTSPLY International Inc. (NASDAQ: XRAY),
NxStage Medical, Inc. (NASDAQ: NXTM), and ICON plc. (NASDAQ: ICLR). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Waters Corporation Research Report

On November 7, 2013, Waters Corporation (Waters) ended the day with stocks
closing at $98.45, down 1.24%. Over the past three trading sessions, Waters'
stocks fell 2.33% while the Dow Jones Industrial Average slid 0.29% during the
same period. The Full Research Report on Waters Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2fff_WAT]

--

PerkinElmer, Inc. Research Report

On October 30, 2013, PerkinElmer, Inc. (PerkinElmer) announced its Q3 FY 2013
financial results (period ended September 29, 2013) with revenues up 2.9% YoY
to $524.3 million. The Company's operating income from continuing operations
increased 32.3% YoY to $57.2 million during the quarter. Net Income from
continuing operations totaled $40.3 million or $0.36 per diluted share in Q3
FY 2013 versus $29 million or $0.25 per diluted share in Q3 FY 2012. Robert
Friel, Chairman and CEO of PerkinElmer said, "I am pleased with our third
quarter performance as we were able to grow both revenue and adjusted earnings
per share and expand operating margins. While I remain encouraged by the
resiliency we are seeing across much of the portfolio, the global economic
environment remains challenging. We believe, however, that the growth and
productivity investments deployed over the past year should help us in the
successful delivery of our full year commitments as we build a strong
foundation for the future." For full-year 2013, PerkinElmer expects EPS from
continuing operations to be in the range of $1.42 to $1.45 and non-GAAP EPS to
be within $2.04 to $2.07. The Full Research Report on PerkinElmer, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2016_PKI]

--

DENTSPLY International Inc. Research Report

On November 7, 2013, stocks of DENTSPLY International Inc. (DENTSPLY) fell
0.38% to $47.15 at the end of trading. DENTSPLY's stocks slid 0.63% over the
previous three trading sessions, while the Dow Jones Industrial Average fell
0.29% during the same period. The Full Research Report on DENTSPLY
International Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/6b01_XRAY]

--

NxStage Medical, Inc. Research Report

On November 7, 2013, NxStage Medical, Inc (NxStage) reported its Q3 2013
financial results with revenues up 9.4% YoY to $66.9 million. NxStage stated
that the increase in revenue was driven by increased adoption of the NxStage®
System One™. For Q3 2013 the Company also reported a 5.6% YoY increase in home
revenues to $33.7 million. Jeffrey H. Burbank, Founder and CEO of NxStage
said, "We continue to make solid progress in strategic areas that are focused
on accelerating growth over the longer term. We're seeing good momentum in the
domestic market and believe our growth opportunity here remains very robust.
In addition to our direct to patient marketing initiatives, we have a
significant opportunity to improve our patients' experiences and increase
adoption of our therapies with both our innovative product pipeline and our
centers of excellence." For Q4 2013, NxStage expects revenues to be within
$67.0 and $68.5 million, and net loss in the range of $6.0 million to $5.0
million. The Company also announced that the US Food and Drug Administration
(FDA) has cleared the Company's Nx2me Connected Health™ solution that provides
new features and capabilities that are important to home dialysis patients and
nurse, and expects to begin offering Nx2me in the US later in 2013. The Full
Research Report on NxStage Medical, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/4654_NXTM

--

ICON plc Research Report

On November 7, 2013, ICON plc's (ICON) ordinary shares rose 1.09% to end the
day at $40.83. Over the past three trading sessions, ICON's stock rose to
0.07% while the Dow Jones Industrial Average slid 0.29% during that period.
The Full Research Report on ICON plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/fbb0_ICLR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)